studiocasper / iStockphoto.com

12 September 2018Americas

Victory for Mylan and Teva as appeals court affirms invalidations

Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?